Braf inhibitor drugs

BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor

Most often, if a person has a BRAF mutation and needs targeted therapy, they will get both a BRAF inhibitor and a MEK inhibitor, as combining these drugs often works better than either one alone. BRAF inhibitors. Vemurafenib (Zelboraf), dabrafenib (Tafinlar), and encorafenib (Braftovi) are drugs that target the BRAF protein directly.

BRAF inhibitors are most often used along with medications that inhibit the growth of a tumor at other points in the signaling pathway (such as MEK inhibitors). Interestingly, adding a MEK inhibitor to a BRAF inhibitor is actually associated with fewer side effects than using a BRAF inhibitor alone. The combination also appears to work for a

Similarly, BRAF gene testing is important in the selection of patients with melanoma who could benefit from BRAF inhibitor therapies.

BRAF inhibitors. BRAF inhibitors include vemurafenib and dabrafenib. Cutaneous adverse effects are common. Hyperkeratotic keratinocytic lesions. Cutaneous

by J Kaltwasser 2024Dabrafenib is a BRAF inhibitor, and trametinib is a MEK inhibitor. The FDA approved the combination therapy in 2024 for patients with BRAF

BRAF/MEK inhibitor. 1:58

Profile Name, BRAF V600E/K ; Gene Variant Detail. BRAF V600E/K (gain of function) ; Relevant Treatment Approaches, BRAF Inhibitor MEK inhibitor (Pan) MEK1

We discovered the mutation of the BRAF gene as the cause of HCL and thereby opened the way to chemotherapy-free strategies that are based on the BRAF inhibitor